A Phase 1 Single Center, Open-Label, Randomized, Three-Way Crossover Study of the Relative Bioavailability of a Single Dose of CTP-656 in a Fasted, Fed Low-Fat and Fed Moderate-Fat Condition in Healthy Male Subjects

Trial Profile

A Phase 1 Single Center, Open-Label, Randomized, Three-Way Crossover Study of the Relative Bioavailability of a Single Dose of CTP-656 in a Fasted, Fed Low-Fat and Fed Moderate-Fat Condition in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Ivacaftor deuterated (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 27 Oct 2016 Results presented at 2016 North American Cystic Fibrosis Conference, as per Concert Pharmaceuticals media release.
    • 27 Oct 2016 Results published in Concert Pharmaceuticals media release.
    • 28 Apr 2016 Status changed from recruiting to completed, as reported by Concert Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top